JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab is a research paper published in Frontiers in Neurology (2025). On theSindex it has a DataRank of 0.104. It has been cited 1 time.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 5R01NS080821-02
CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study
National Institutes of Health
Grant: 2T32HD007505-21
Training Program in Organogenesis
National Institutes of Health
Grant: 5UM1AI110557-05
University of Michigan Autoimmunity Center of Excellence, Clinical Research Progr
FWCI
0.46
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals